Comparative Pharmacology
Head-to-head clinical analysis: REGONOL versus RIVASTIGMINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGONOL versus RIVASTIGMINE TARTRATE.
REGONOL vs RIVASTIGMINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases involved in angiogenesis, oncogenesis, and tumor microenvironment, including VEGFR1-3, TIE2, PDGFR-β, FGFR1, KIT, RET, RAF-1, and BRAF.
Reversible, non-competitive inhibitor of acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine concentration in the CNS.
Intravenous: 400 mg every 12 hours for 60 doses. Maintenance: 400 mg twice daily for 180 days (6 months).
Initial 1.5 mg orally twice daily; increase by 1.5 mg twice daily at ≥2-week intervals to maximum 6 mg twice daily if tolerated.
None Documented
None Documented
Terminal half-life of 2–4 hours; clinically relevant for dosing every 6–8 hours in renal impairment.
The terminal elimination half-life is approximately 1.5 hours after oral administration. However, due to slow dissociation from the cholinesterase enzyme, the pharmacodynamic half-life (duration of enzyme inhibition) is about 10 hours, supporting twice-daily dosing.
Approximately 70% renal (unchanged) and 30% biliary/fecal as glucuronide conjugates.
Rivastigmine is extensively metabolized by cholinesterase-mediated hydrolysis to the inactive decarbamylated metabolite, NAP226-90, which is then excreted renally. Approximately 97% of a dose is excreted in urine as metabolites (<1% as parent drug), and about 0.4% in feces. Renal elimination accounts for >90% of total clearance.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor